Status:

COMPLETED

PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort

Lead Sponsor:

Karolinska Institutet

Collaborating Sponsors:

The Swedish Research Council

Conditions:

Obsessive-compulsive Disorder With Acute Onset

PANDAS

Eligibility:

All Genders

Brief Summary

Background: Obsessive-compulsive disorder (OCD) is considered one of the most debilitating of the psychiatric illnesses, yet much remains unclear regarding causes and cures. A diagnostic subgroup with...

Detailed Description

Data collected comprises: Retrospective data * Interview * Medical records * Five to Fifteen (FTF) * Cunningham panel of PANS biomarkers result prior to inclusion (at time point 1) * Change in Clini...

Eligibility Criteria

Inclusion

  • Inclusion Criteria the PANS-group:
  • Scandinavian patients assessed with the Cunningham panel through Wieslab, Lund, Sweden or Statens Serum Institut (SSI), Copenhagen, Denmark.
  • Exclusion Criteria PANS-group:
  • intellectual disability, non-Swedish speaking
  • Inclusion Criteria Psychiatric Controls:
  • diagnosed with a psychiatric disorder
  • age \<40 years
  • Exclusion Criteria Psychiatric Controls:
  • intellectual disability, non-Swedish speaking
  • Inclusion Criteria Healthy Controls:
  • age and sex matched to the PANS-group
  • Exclusion Criteria Healthy controls:
  • intellectual disability, non-Swedish speaking

Exclusion

    Key Trial Info

    Start Date :

    June 1 2014

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    185 Patients enrolled

    Trial Details

    Trial ID

    NCT02190292

    Start Date

    June 1 2014

    Last Update

    October 22 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Northern Stockholm psychiatry

    Stockholm, Sverige, Sweden, SE-112 81

    PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort | DecenTrialz